The federal government is loosening its grip on low-risk digital health tools, but developers who mismanage their marketing claims will still face regulatory crackdowns.

The FDA is shifting its approach to wellness wearables and clinical decision support software. By expanding enforcement discretion, regulators are trying to spur investment and clear out bureaucratic bottlenecks.

But this is not a free pass. It is a calculated trade-off.

The Real-World Test

Under the new TEMPO pilot, closely tied to a CMS Innovation Center initiative launching in July 2026, chronic-care device makers can bypass traditional hurdles. They can gather real-world clinical data while operating under enforcement discretion.

This creates a fast track for product development.

However, the boundary between “wellness” and “medical device” remains razor-thin.

The Marketing Trap

The regulatory relief only lasts as long as a company’s marketing remains strictly general. The moment a wearable maker claims their tool diagnoses or treats a specific disease, the FDA’s heavy regulatory machinery kicks back in.

For developers, the temptation to make bold medical claims is high.

Yielding to that temptation will trigger the very oversight they are trying to avoid. The strategy here is clear. The government wants rapid innovation, but it is shifting the burden of compliance entirely onto how these products are framed to the public.